The UMR-996 is an INSERM and university laboratory including three teams (~50 scientists), which belongs to the large Paris-Sud University perimeter. One of the three teams investigates various aspects of the biology and physiopathology of chemokine receptors (cancer immunodeficiencies, autoimmune and virus-induced diseases) with a special focus on the CXCR4/CXCR7-ACKR3 receptors. Scientists of the team combine expertise in Virology (host/oncovirus interactions and viral persistence), Immunology (immune responses against oncovirus and immunomodulation in the tumoral microenvironment), Pharmacology (structure/function studies of CXCL12/receptors and specific inhibitors) and Physiopathology (CXCR4-related primary immunodeficiencies and autoimmunities) and are working in close interactions with clinicians. The host laboratory is also part of a consortium of excellence (LabEx LERMIT) dealing with research on medication and innovative therapeutics in the context of which the partner’s project aims at developing new antagonists of the CXCL12/CXCR4/CXCR7-ACKR3 ligand/receptors axis.
Key research facilities, infrastructures and equipment
The partner benefits from on-site equipment for biochemistry, molecular biology, flow-cytometry, cellular biology and belongs to a federative structure (SFR-Institut Paris-Saclay Innovation Thérapeutique - (www.ipsit.ifr141.u-psud.fr/fr/page/bienvenue-a-l-ipsit/62-presentation-de-l-ipsit.html), which includes on-site and local technological platforms such as imaging (high and super-resolution confocal microscopes), proteomics and transcriptomics, spectrometry (LTQ-Orbitrap XL), animal facilities, flow and innovative mass cytometry (CyTOF®) technologies, molecular screening including in-house chemical libraries, and histological analysis with virtual microscopy resources.